COV Stock Overview
Engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Covalon Technologies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.27 |
| 52 Week High | CA$2.40 |
| 52 Week Low | CA$0.96 |
| Beta | 0.52 |
| 1 Month Change | 124.75% |
| 3 Month Change | 89.17% |
| 1 Year Change | 19.47% |
| 3 Year Change | 49.34% |
| 5 Year Change | -54.78% |
| Change since IPO | -24.33% |
Recent News & Updates
Covalon Technologies (CVE:COV) Is In A Good Position To Deliver On Growth Plans
May 01
Covalon Technologies Ltd.'s (CVE:COV) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Feb 17Recent updates
Covalon Technologies (CVE:COV) Is In A Good Position To Deliver On Growth Plans
May 01Covalon Technologies Ltd.'s (CVE:COV) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Feb 17Insufficient Growth At Covalon Technologies Ltd. (CVE:COV) Hampers Share Price
Dec 22We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business Growth
Sep 02We Think Covalon Technologies (CVE:COV) Needs To Drive Business Growth Carefully
May 26Is Covalon Technologies (CVE:COV) Using Too Much Debt?
Apr 29Covalon Technologies (CVE:COV) Is Making Moderate Use Of Debt
Dec 29Shareholder Returns
| COV | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 108.3% | 7.1% | -1.4% |
| 1Y | 19.5% | -28.0% | 11.2% |
Return vs Industry: COV exceeded the Canadian Biotechs industry which returned -25.6% over the past year.
Return vs Market: COV exceeded the Canadian Market which returned 11.9% over the past year.
Price Volatility
| COV volatility | |
|---|---|
| COV Average Weekly Movement | 22.4% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: COV's share price has been volatile over the past 3 months.
Volatility Over Time: COV's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Brent Ashton | www.covalon.com |
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device.
Covalon Technologies Ltd. Fundamentals Summary
| COV fundamental statistics | |
|---|---|
| Market cap | CA$53.78m |
| Earnings (TTM) | -CA$2.77m |
| Revenue (TTM) | CA$26.24m |
2.1x
P/S Ratio-20.2x
P/E RatioIs COV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COV income statement (TTM) | |
|---|---|
| Revenue | CA$26.24m |
| Cost of Revenue | CA$11.59m |
| Gross Profit | CA$14.65m |
| Other Expenses | CA$17.43m |
| Earnings | -CA$2.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 55.84% |
| Net Profit Margin | -10.57% |
| Debt/Equity Ratio | 0% |
How did COV perform over the long term?
See historical performance and comparison